Journal Articles
The following is a list of peer-reviewed journal articles pertaining to the microbiota-based products currently under development in the MRT™ drug platform. Click on the title to view complete information.
Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic
Ken F. Blount, William D. Shannon, Elena Deych, and Courtney Jones
Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-based Drug Targeted at Recurrent Clostridium difficile Infection
Erik R. Dubberke, Kathleen M. Mullane, Dale N. Gerding, Christine H. Lee, Thomas J. Louie, Harriet Guthertz, and Courtney Jones
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study
Robert Orenstein, Erik Dubberke, Robert Hardi, Arnab Ray, Kathleen Mullane, Darrell S. Pardi, and Mayur S. Ramesh; for the PUNCH CD Investigators
White Papers by Rebiotix
The following is a list of white papers by Rebiotix on subjects related to our industry and science. Click on the white paper title to view full details.
The Human Microbiome: A New Frontier in Drug Discovery
Published Summer 2016
Lee Jones, CEO, Rebiotix Inc.
What’s Next for the Microbiome: View from Industry
Published June 2015